How much of Freeline Therapeutics'stock is owned by institutions?
Only 29.18% of the stock of Freeline Therapeutics is held by institutions. Earnings for Freeline Therapeutics are expected to grow in the coming year, from ($3.56) to ($2.62) per share. Freeline Therapeutics has a P/B Ratio of 0.19.
What are analysts'target prices for Freeline Therapeutics'stock?
9 Wall Street analysts have issued 12-month target prices for Freeline Therapeutics' stock. Their forecasts range from $8.00 to $27.00. On average, they anticipate Freeline Therapeutics' share price to reach $16.88 in the next year. This suggests a possible upside of 1,208.1% from the stock's current price.
When is Freeline Therapeutics'next quarterly earnings announcement?
Freeline Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022. View our earnings forecast for Freeline Therapeutics. How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its quarterly earnings results on Tuesday, November, 9th.
Is freeline Therapeutics a good investment?
Valuation metrics show that Freeline Therapeutics Holdings PLC Sponsored ADR may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of FRLN, demonstrate its potential to underperform the market.
Will freeline Therapeutics stock go up?
The 6 analysts offering 12-month price forecasts for Freeline Therapeutics Holdings PLC have a median target of 6.50, with a high estimate of 20.00 and a low estimate of 2.00. The median estimate represents a +606.52% increase from the last price of 0.92.
Should I buy or sell Freeline Therapeutics stock right now?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 3 hol...
What is Freeline Therapeutics' stock price forecast for 2022?
8 Wall Street research analysts have issued 1-year target prices for Freeline Therapeutics' stock. Their forecasts range from $8.00 to $20.00. On a...
How has Freeline Therapeutics' stock performed in 2022?
Freeline Therapeutics' stock was trading at $1.98 at the start of the year. Since then, FRLN stock has decreased by 62.1% and is now trading at $0....
When is Freeline Therapeutics' next earnings date?
Freeline Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for...
How were Freeline Therapeutics' earnings last quarter?
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) released its earnings results on Tuesday, May, 10th. The company reported ($0.63) earnings per sha...
Who are Freeline Therapeutics' key executives?
Freeline Therapeutics' management team includes the following people: Mr. Michael J. Parini J.D. , CEO, COO, Pres & Exec. Director (Age 47, Pay...
Who are some of Freeline Therapeutics' key competitors?
Some companies that are related to Freeline Therapeutics include Jounce Therapeutics (JNCE) , Genfit (GNFT) , Dynamics Special Purpose (DYNS) ,...
What other stocks do shareholders of Freeline Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE) ,...
When did Freeline Therapeutics IPO?
(FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per...
Freeline Therapeutics (NASDAQ:FRLN) Price Target and Consensus Rating
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for FRLN and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Freeline Therapeutics (NASDAQ:FRLN) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
